CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-14 | Pera Antonio R Director | Sale 10b5-1 | −3,000 | $60.37 | $181K | 33,627 |
| 2023-08-11 | Lalwani Nikhil PRESIDENT & CEO | Sale | −56,666 | $57.75 | $3.3M | 353,390 |
| 2023-08-01 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $51.06 | $1.0M | 333,226 |
| 2023-07-21 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −11,500 | $52.56 | $604K | 1,232,620 |
| 2023-07-20 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −6,000 | $51.52 | $309K | 1,244,120 |
| 2023-07-19 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −5,969 | $51.48 | $307K | 1,250,120 |
| 2023-07-18 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Shares withheld for taxes | −1,743 | $51.89 | $90K | 37,799 |
| 2023-07-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −6,700 | $51.84 | $347K | 1,256,089 |
| 2023-07-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −9,831 | $51.06 | $502K | 1,262,789 |
| 2023-07-14 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,000 | $50.43 | $504K | 1,272,620 |
| 2023-07-03 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $53.43 | $1.1M | 353,226 |
| 2023-06-23 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,000 | $51.49 | $515K | 1,282,620 |
| 2023-06-22 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −13,500 | $51.38 | $694K | 1,292,620 |
| 2023-06-22 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $51.32 | $1.0M | 373,226 |
| 2023-06-22 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −13,500 | $51.38 | $694K | 7,407 |
| 2023-06-21 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −11,843 | $51.95 | $615K | 1,306,120 |
| 2023-06-21 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −11,843 | $51.95 | $615K | 20,907 |
| 2023-06-20 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −14,657 | $51.93 | $761K | 1,317,963 |
| 2023-06-20 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −14,657 | $51.93 | $761K | 32,750 |
| 2023-05-23 | TANNENBAUM RENEE P Director | Grant or award | +6,865 | 20,211 |
Page 19 of 23 · 442 trades